MediWound Q2 FY26 net loss narrows to USD 7.4 million; revenue drops to USD 3.1 million
MDWD•Full-year guidance
Full-year 2026 revenue guidance of USD 24 million to USD 26 million was reaffirmed, with MSA revenue under Vericel’s BARDA contract expected in H2 2026.
Q2 results and operating trends
MediWound posted Q2 revenue of USD 3.1 million, down 45.85% year over year; operating loss widened to USD 9.5 million.
Net loss narrowed to USD 7.4 million, or USD 0.57 per share, versus USD 13.3 million, on non-cash financial income.
R&D expense rose to USD 5.9 million from USD 3.5 million, reflecting higher investment in the EscharEx Phase III VALUE trial.
Cash, cash equivalents and deposits totaled USD 36 million at June 30, down from USD 54 million at year-end 2025.
